MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'exelixis'. Sat, 03 Sep 2011 02:48:45 +0100 http://www.medworm.com/index.php?rid=4704958&cid=t_104969_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FhWBKw4PwEO0%2F Top of the morning to you. Gray skies are hovering over the Pharmalot corporate campus this morning, where we are hustling the short people off to the school house for some learning and quaffing our usual cup of stimulation - our flavor today is Mocha Fudge Nut. Please join us. While you do, here are some tidbits from around your universe. We hope your day is productive and rewarding. Meanwhile, let us know of anything interesting or unusual. Have a great one… Study Reveals New Target For Antidepressants (Reuters) Teva MS Pill Reduces Relapses Less Most Injectables (Bloomberg News) Glaxo Moving More Jobs To Scotland (Scotland Herald) FDA Approves Merck Skin Cancer Drug (Reuters) Biogen MS Pill Shows Promise In Study (Associated Press) UK Docs May Consider Cost When Prescribing Off-La... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4704958 Tue, 12 Apr 2011 12:07:42 +0100 4704958 http://www.medworm.com/index.php?rid=2035949&cid=t_104969_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F482661218%2F The drugmaker has inked a pact with Exelixis to work on two experimental compounds in the latest sign of big pharma turning to biotech to shore up a pipeline. The deal, of course, also reflects the need of biotechs to rely on big drugmakers as financing options grow dimmer. Under the deal, Bristol-Myers will pay $195 million now and another $45 million in 2009 to codevelop the drugs, with several hundred million dollars in additional payments if milestones are met, making the upfront payment one of the biggest amounts a big drugmaker has paid in such agreements (here is the Bristol-Myers statement). Nonetheless, a Bristol-Myers exec says the agreement reflects a competitive market for compounds viewed as especially promising. “We’re not the only company out there looking for go... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2035949 Fri, 12 Dec 2008 13:08:35 +0100 2035949 http://www.medworm.com/index.php?rid=1895584&cid=t_104969_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2008%2F10%2F22%2Fwo2008124161%2F Exel’s got Pi3K-a in combination: Reminds one of the XL-147 combo study. So thats XL-647 ?  I hadn’t heard. Posted in EGF, Exelixis, pi3k       (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=1895584 Wed, 22 Oct 2008 12:05:46 +0100 1895584 http://www.medworm.com/index.php?rid=1065936&cid=t_104969_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F12%2F03%2Fpiper-jaffray%2F …It’s an investor dog and pony show, and it was last week. Who was there? Exelixis: George Scangos had this to say on Kinase selectivity: We get a lot of questions about whether we think that less specific multi-targeted kinase inhibitors are better then more specific kinase inhibitors. I think there is no general answer to that question. Personal view is when your working on the outside of the cell inhibiting a single molecule leads to efficacy, but the efficacy is limited and you can greatly increase the potency by hitting multiple targets at the same time without increasing the toxicity significantly, and I think there is plenty of clinical data now to show that that’s true. On the other hand when your working downstream inside the cell in the biochemical pathway I think... KinasePro blogs http://www.medworm.com/rss/comments.php?id=1065936 Mon, 03 Dec 2007 05:16:16 +0100 1065936 http://www.medworm.com/index.php?rid=799389&cid=t_104969_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F08%2F14%2Fwo2007089768%2F 27 Authors, 586 pages, a whole bunch of examples, and 20 MB of Jak-2 goodness. Seems likely that XL-019 came out of this series. (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=799389 Tue, 14 Aug 2007 22:02:06 +0100 799389 http://www.medworm.com/index.php?rid=571385&cid=t_104969_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F112120430%2Fusfda_gave_go_signal_to_exelix.html The USFDA has granted Exelixis, Inc. (Nasdaq: EXEL) the go signal to initiate its clinical trial (following approved review of the protocol) of XL999 in patients with non-small cell lung cancer (NSCLC). Developed by Exelixis, XL999 is a potent inhibitor of key receptor tyrosine kinases (RTKs) implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells. According to George A. Scangos, PhD, president and chief executive officer of Exelixis: "We have worked closely with the FDA to reinitiate the clinical development of XL999 and believe that the approved protocol will enable us to assess both safety and preliminary anti-tumor activity of the compound in patients with NSCLC. In the previous Phase 2 clinical trial of XL999 in NSCLC patien... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=571385 Thu, 26 Apr 2007 11:44:45 +0100 571385 http://www.medworm.com/index.php?rid=486691&cid=t_104969_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F102844957%2Fexelixis_submitted_ind_for_can.html Exelixis, Inc. (Nasdaq: EXEL) has recently submitted an investigational new drug (IND) application to the USFDA for its candidate anticancer compound XL147. XL147 is a novel, orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In human tumors, activation of PI3K is frequent – thereby promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. According to Gisela M. Schwab, MD, senior vice president and chief medical officer at Exelixis: "A growing body of data indicates that inappropriate activation of the PI3K signaling pathway is a common feature of human tumors and may result from dysregulation at multiple points along the signaling cascade. We are therefore evaluating multiple compounds that ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=486691 Mon, 19 Mar 2007 04:05:29 +0100 486691